dermatological, gastroenterology, and pain killer medicines in the near future, and to progressively extend its product range. At its Khatraj plant, the firm produces a wide variety of drugs. It manufactures antimicrobials and medicines for conditions affecting the respiratory system, diabetes, and dermatitis, and others. The pharmaceutical company has previously obtained European Union (EU) Good Manufacturing Practice (GMP) accreditation, enabling it to sell its goods in all 27 member nations.
Mahendra Patel, Lincoln Pharmaceuticals Managing Director, expressed hopes about the licence. He said, “TGA and EU GMP approval are important stepping stones in the journey of the company and will help to expand its presence in more regulated markets”. He highlighted that TGA and EU GMP certifications are the outcome of Lincoln Pharma’s high quality and compliance standards being followed across all areas, particularly R&D and compliance.
Patel expressed optimism over the progress of the company. He said, “Over the years, the company has seen good traction in the export business, which is expected to get a further boost once TGA & EU operations commence. The certification will allow us to address the growing needs of patients in the regulated markets and provide affordable and innovative medicines”. According to him, the TGA and EU certifications would enable the company to progress its commercial network to more than 90 nations. At present, the firm does business with more than 60 nations worldwide, including East and West Africa, Central and Latin America, and Southeast Asia.
